Products

Velacur
Sonic Incytes Medical Corp.
Gastroenterology AI
Velacur by Sonic Incytes is an AI-guided, portable, point-of-care ultrasound elastography device for non-invasive assessment of liver stiffness, attenuation, and fat content, aiding in the management of chronic liver diseases like MASLD and MASH. It is not a physician directory tool.

See all 1 product →

About Sonic Incytes Medical

Sonic Incytes Medical Corp. is a health technology company at the forefront of addressing the global epidemic of chronic liver disease, specifically Metabolic dysfunction–associated steatotic liver disease (MASLD) and Metabolic dysfunction–associated steatohepatitis (MASH). Their flagship product, Velacur™, is an innovative, portable, and handheld point-of-care ultrasound elastography device engineered to deliver accessible, affordable, and accurate non-invasive liver assessments directly at the point of care.

Velacur™ leverages proprietary technology akin to MRI elastography, utilizing steady-state waves to precisely quantify liver tissue stiffness and attenuation. A key feature of the device is its AI-guided output measurement for liver fat, known as Velacur Determined-Fat Fraction (VDFF). This VDFF algorithm received FDA clearance in 2024 and has demonstrated a strong correlation (r = 0.85) with MRI-PDFF, which is considered the gold standard for liver fat measurement. The system facilitates 3D tissue sampling and provides immediate, highly accurate results, empowering physicians to confidently diagnose, monitor, and manage chronic liver conditions within approximately five minutes during a patient’s office visit.

The company’s overarching mission is to establish liver health as a new vital sign by offering a cost-effective diagnostic solution that can be seamlessly integrated into diverse clinical settings with minimal upfront investment. Velacur™ aims to significantly enhance the early detection and ongoing monitoring of MASLD and MASH, conditions that are frequently underdiagnosed and can lead to severe complications, including cirrhosis, liver failure, and cancer, if left unaddressed. Furthermore, the device’s AI-based scanning guide is designed to improve ease of use, making accurate scans more achievable for non-expert users and potentially paving the way for broader adoption in primary care settings.

Focus Areas

Chronic liver disease Fatty liver disease MASLD MASH Liver stiffness Liver attenuation Point-of-care ultrasound AI-guided diagnostics Non-invasive liver assessment Ultrasound elastography

Business Intelligence

Key InvestorsNimbus Synergies, Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels, INP Capital, INOVAIT Focus Fund, Genome BC, Small World Group, Think Top Investments, Sunhope Venture Capital, World Changing Ventures, TMFOX, UBC Seed Fund, E-Fund, Mana Ventures, MEDTEQ Invest, Quimby Investments, Pacific Hi-Tech
PartnershipsMadrigal Pharmaceuticals (clinical trial), Northwell Health (Velacur trial)
TechnologyPoint-of-care ultrasound elastography, 3D S-WAVE technology, AI-based scanning guide (Organ Guide, Wave Quality Detector), Velacur Determined-Fat Fraction (VDFF) algorithm, external activation source for shear wave generation, cloud-native (implied by AI guidance and data transfer)
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Specialization in Chronic Liver Disease & Fatty Liver Disease
Sonic Incytes Medical specializes in the non-invasive assessment and management of chronic liver diseases, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). They address the critical need for early detection and ongoing monitoring in these rapidly growing conditions.
Comprehensive Liver Assessment Parameters
Their flagship device, Velacur ONEu2122, measures three key liver parameters: liver stiffness (for fibrosis assessment), attenuation (quantifying tissue changes), and Velacur Determined-Fat Fraction (VDFF), a proprietary fat quantification metric.
Point-of-Care Ultrasound & Non-invasive Assessment
Velacur ONE is a portable, handheld point-of-care ultrasound elastography device designed for convenient, non-invasive liver assessment directly in a physician's office. The procedure is quick, comfortable, and can be performed in about five minutes.
AI-Guided Diagnostics & Ultrasound Elastography
The device incorporates AI-guided functions for real-time operator assistance, facilitating liver identification and optimizing wave quality, making it accessible for operators with varying sonography experience. It utilizes S-WAVE technology for advanced ultrasound elastography.
Physician Tip

Sonic Incytes Medical's Velacur ONE offers physicians a powerful, accessible tool for managing chronic liver diseases. Its AI-guided, non-invasive approach simplifies liver assessment, providing quantitative data on liver stiffness, attenuation, and fat fraction (VDFF) that correlates strongly with MRI-PDFF, the gold standard for liver fat measurement. This enables confident diagnosis, monitoring of disease progression, and assessment of treatment response, particularly crucial with the emergence of new MASH therapeutics. The device's portability, ease of use (even for non-sonographers), and potential for higher reimbursement (3-4x higher than non-imaging elastography) make it an economically attractive and clinically valuable addition to point-of-care settings. It aligns with current clinical guidelines for screening high-risk patients and can significantly improve patient management by providing immediate, actionable insights.

Velacur ONE is designed for seamless integration into existing clinical workflows at the point of care. Its pre-installed AI-guided software and comprehensive training program enable medical professionals, including medical assistants and nurse practitioners, to operate the device efficiently and effectively. The device's ability to provide immediate, quantitative results supports rapid clinical decision-making and patient counseling without the need for external imaging specialists or complex data interpretation. Its B-mode imaging capabilities further enhance its utility and potential for improved reimbursement.

Products by Sonic Incytes Medical

1 product in the directory

Velacur
Sonic Incytes Medical Corp.
Gastroenterology AI
Velacur by Sonic Incytes is an AI-guided, portable, point-of-care ultrasound elastography device for non-invasive assessment of liver stiffness, attenuation, and fat content, aiding in the management of chronic liver diseases like MASLD and MASH. It is not a physician directory tool.

What the Web Says

Sonic Incytes Medical is a company focused on developing AI-guided, non-invasive ultrasound technology for assessing and monitoring chronic liver disease. Their flagship product, Velacur, and its next-generation version, Velacur ONE, have received FDA clearance and are designed to provide real-time, accurate measurements of liver stiffness, attenuation, and fat content at the point of care. While the technology and its mission are praised, employer reviews indicate significant issues with leadership and workplace culture.

Overall: Mixed

Strengths

  • Breakthrough, handheld ultrasound solution for chronic liver disease assessment.
  • Velacur ONE offers AI-guided, real-time quantification of liver stiffness, attenuation, and VDFF (Velacur Determined-Fat Fraction).
  • High accuracy (95%) in detecting hepatic steatosis.
  • Comparable to MRI for liver fat quantification, considered the gold standard.
  • Enhanced portability and redesigned interface in Velacur ONE.
  • Affordable and accessible point-of-care liver imaging.

Limitations

  • Toxic/abusive leadership.
  • Negative work environment and culture.
  • Employees feel that nobody can accomplish anything due to senior leadership.

Based on reviews from: Indeed.com, AuntMinnie, Patsnap Synapse, Sonic Incytes Website

Last updated: 2026-07-20

Videos

News, demos, and interviews about Sonic Incytes Medical.

Loading videos...

Videos load interactively. If none appear, search YouTube for Sonic Incytes Medical →

View all on YouTube

Press & Coverage

Sonic Incytes
Sonic Incytes Named 2026 MedTech Emerging Company of the Year
Sonic Incytes has been recognized by Life Sciences BC as the 2026 Emerging Company of the Year u2013 MedTech for its significant contributions to British Columbia's life sciences community through growth, innovation, and impact. The award highlights their progress in liver disease assessment with Velacur ONEu2122, an AI-guided ultrasound device.
2026-06
Sonic Incytes / Business Wire
FDA Grants 510(k) Clearance for Sonic Incytes' Velacur ONEu2122, AI-guided point of care ultrasound for the management of chronic liver diseases
Sonic Incytes Medical Corp. announced that the U.S. FDA has granted 510(k) clearance for Velacur ONEu2122, its AI-guided point-of-care ultrasound elastography device for managing chronic liver diseases. This enhanced version of Velacuru2122 offers improved portability and user experience, arriving at a crucial time for non-invasive testing following the FDA clearance of Rezdiffra for MASH.
2025-08
Imaging Technology News
Sonic Incytes' AI-Guided POCUS Device for Managing Chronic Liver Diseases Gets FDA Nod
Sonic Incytes Medical Corp. received FDA 510(k) clearance for Velacur ONE, an AI-guided point-of-care ultrasound elastography device designed to manage chronic liver diseases like MASH and MASLD. The device measures attenuation, VDFF (Velacur Determined-Fat Fraction), and liver stiffness using 3D S-WAVE technology.
2025-08
AuntMinnie.com
FDA clears Sonic Incytes' POCUS device
Vancouver, BC-based Sonic Incytes Medical has secured U.S. FDA clearance for its point-of-care ultrasound (POCUS) elastography device, Velacur One, which measures attenuation and liver stiffness using 3D S-WAVE and features a new AI output measurement for liver fat called Velacur Determined-Fat Fraction.
2025-08
Diagnostics (Basel)
Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard
This peer-reviewed article discusses the accuracy of Velacur, a point-of-care ultrasound-based elastography assessment tool from Sonic Incytes Medical Corp., for evaluating patients with chronic liver disease, specifically MASLD and MASH, using biopsy as the gold standard.
2025-03
WFUMB Ultrasound Open
Methods and Validation of Velacur Determined Fat Fraction in Patients with MASLD
This publication details the methods and validation of Sonic Incytes' proprietary Velacuru00ae Determined Fat Fraction (VDFF) algorithm in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). VDFF demonstrates a strong correlation with MRI-PDFF, the gold standard for liver fat measurement.
2024-01
Sonic Incytes
Sonic Incytes Announces New Non-Dilutive Funding to Enhance Company's Velacuru2122ufe0f Medical Device
Sonic Incytes Medical Corp. announced that its project was selected for investment by the inaugural INOVAIT Focus Fund, providing up to CDN $1.18M in non-dilutive funding to enhance Velacuru2122 with an AI-based scanning guide.
2023-01
GlobeNewswire
Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacuru2122 Commercialization
Sonic Incytes Medical Corp. completed a US$7.3M Series A funding round, oversubscribed by 150%, with Nimbus Synergies as the lead investor. This funding will accelerate the commercialization of Velacuru2122, their handheld 3D liver health assessment solution.
2021-12

Frequently Asked Questions

Velacur ONEu2122 is an FDA-cleared, AI-guided point-of-care ultrasound elastography device that non-invasively measures liver stiffness (fibrosis), attenuation, and Velacur-determined fat fraction (VDFF). It provides a comprehensive assessment of liver health, crucial for diagnosing and managing chronic liver diseases like MASLD and MASH, and has shown strong correlation with MRI-PDFF for fat assessment.
Velacur ONEu2122 utilizes AI guidance and 3D S-WAVE technology to offer deeper measurements and larger tissue samples (2X depth and 30X volume of transient elastography), even in high BMI patients. Its VDFF algorithm has demonstrated superior accuracy for detecting steatosis compared to FibroScan CAP, while providing comparable accuracy for fibrosis assessment.
Sonic Incytes Medical has received FDA 510(k) clearance for its Velacur ONEu2122 device, including its proprietary Velacur-determined fat fraction (VDFF) algorithm. These clearances affirm the device's safety and effectiveness for use in managing chronic liver diseases.
Velacur ONEu2122 is designed for ease of use at the point of care, featuring AI guidance such as an Organ Guide and Wave Quality Detector that assist operators in real-time, regardless of their sonography experience. Sonic Incytes provides comprehensive training, including online learning and hands-on experience, enabling trained medical professionals like MAs and NPs to confidently perform scans.
Velacur ONEu2122 procedures are billable using CPT code 76981 for ultrasound elastography, which applies to parenchyma (e.g., organ) assessment. The device's combination of VDFF and B-mode imaging can facilitate higher reimbursement compared to non-imaging elastography.
Founded in 2017, Sonic Incytes Medical is a venture capital-backed company that has successfully completed a Series A funding round and raised over $39.4M in total funding. The company is actively pursuing accelerated US and global expansion, aiming to make liver health a new vital sign through accessible, affordable, and accurate diagnostic solutions.
Velacur ONEu2122's efficacy is supported by peer-reviewed publications demonstrating its accuracy against biopsy and superior performance over FibroScan for steatosis detection, with strong correlation to MRI-PDFF. Sonic Incytes actively collaborates with key centers of excellence in chronic liver disease across North America for rigorous clinical research and has participated in studies like Madrigal Pharmaceutical's MAESTRO NAFLD-1.

Related Companies

Visiopharm is a leading provider of AI-driven precision pathology software, catering to both research and diagnostic applications. For physicians, Visiopharm offers advanced tools that transform pathology through image analysis, aiming to enhance precision and productivity in pathology labs. The company has developed nine diagnostic algorithms cleared under IVDR for EU and UK customers, which provide […]

TSI (Transworld Systems Inc.) is a long-standing company primarily known for its debt collection and business process outsourcing services. While they serve various industries, including healthcare, their core offering is focused on accounts receivable management and collections rather than healthcare-specific AI development. They provide solutions to help healthcare providers manage patient accounts, improve cash flow, […]

TrialX is a healthcare AI company specializing in clinical research and space health informatics. The company develops platforms designed to connect patients with clinical trials and facilitate research data collection. Their offerings include an enterprise patient recruitment platform (iConnect) that provides a clinical trials finder (Dory), study website builders, pre-screeners, referral tracking, and volunteer registries. […]

Thinkitive is a global IT services and solutions company that specializes in digital transformation, enterprise application services, outsourced product development, and a testing center of excellence. For physicians, Thinkitive offers a range of AI-driven healthcare solutions designed to streamline clinical and administrative workflows, enhance patient care, and improve operational efficiency. Their services include custom healthcare […]

Taction Software is a U.S.-based healthcare IT and custom software development company specializing in HIPAA-compliant solutions. They build AI-powered applications for healthcare, ranging from rapid clinical AI prototypes to production-grade systems with EHR integration, ambient documentation, and predictive analytics. The company focuses on transforming healthcare delivery through secure, compliant, and innovative software solutions that aim […]

SUPERWISE offers an enterprise AI governance and operations platform designed to help organizations, including those in healthcare, deploy and manage autonomous AI systems with oversight and control. The platform addresses governance, compliance, and operational challenges associated with AI and machine learning deployments. It features real-time guardrails for AI systems, model observability capabilities, and compliance automation, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.